Categories: EHRNewsPharmaceutical

Travere Therapeutics to Report Second Quarter 2023 Financial Results

SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2023 financial results on Thursday, August 3, 2023, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

The webcast and dial-in information can be accessed on the Investor page of Travere’s website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company’s website.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

Investors: Media:
Naomi Eichenbaum Nivi Nehra
Vice President, Investor Relations Vice President, Corporate Communications
888-969-7879 888-969-7879
ir@travere.com mediarelations@travere.com

Staff

Recent Posts

Zepp Health Introduces Zepp OS 4: Redefining Wearable Intelligence by Integrating OpenAI’s GPT-4o into its Amazfit Smartwatches

Amazfit Active becomes the world's first smartwatch under €200 to fully-integrate AI. MILPITAS, Calif., July…

1 hour ago

Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325

Investment will support investigation of Mission's small molecule drug MTX325 in patients with early-stage Parkinson's…

1 hour ago

Clarivate Identifies Six Breakthrough MedTech Trends in 2024 Set to Unlock New Industry Opportunities

New report highlights challenges and opportunities in resilient MedTech industry LONDON, July 2, 2024 /PRNewswire/…

1 hour ago

Poolbeg Pharma PLC Announces Change of Registered Address

Change of Registered AddressLONDON, UK / ACCESSWIRE / July 2, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ('Poolbeg'…

4 hours ago

IRLAB’s Phase IIb Study of Pirepemat Can Proceed as Planned after Positive Opinion from External Safety Committee

GOTHENBURG, SWEDEN / ACCESSWIRE / July 2, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July…

4 hours ago